Abstract
The δ-opioid receptor (DOR) is a promising target for developing novel analgesics due to its lower risk of causing side effects compared to the μ-opioid receptor (MOR), which is commonly associated with dependence, respiratory depression, and other adverse effects. KNT-127, a DOR-selective agonist with a morphinan skeleton, offers analgesic and antidepressant benefits without inducing convulsions at therapeutic doses, unlike the conventional DOR agonist SNC80. While previous studies have suggested that KNT-127 exhibits reduced β-arrestin recruitment, a signaling pathway implicated in adverse opioid effects, the ligand structural basis for this biased signaling remains unclear. In this study, we explored the structure–signal relationships of KNT-127, focusing on its quinoline moiety. Modifying the quinoline moiety by removing the aromatic rings reduced DOR selectivity and potency in relation to G-protein activation while diminishing both the potency and efficacy of β-arrestin recruitment. These results suggest that the morphinan skeleton is critical for reduced β-arrestin recruitment, while the quinoline moiety differentially modulates G-protein activation and β-arrestin recruitment. Together, our study thus provides structural insights into the G-protein-biased agonism of DOR agonists, guiding the design of safer DOR-targeting therapeutics.
Supplementary materials
Title
Supplementary materials
Description
1H and 13C NMR spectra of the assayed compounds. Figure S1: Structural determination of KNT-127. Figure S2: Structural determination of 12. Figure S3: Concentration-response curves of Met-Enk, KNT-127, 1, and 2 against the opioid receptors.
Actions